Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Human milk oligosaccharides 3'-sialyllactose and 6'-sialyllactose attenuate LPS-induced lung injury by inhibiting STAT1 and NF- κB signaling pathways
Arch Pharm Res. 2023 Nov 9. doi: 10.1007/s12272-023-01470-1. Online ahead of print.ABSTRACTAcute lung injury (ALI) is the leading cause of respiratory diseases induced by uncontrolled inflammation and cell death. Lipopolysaccharide (LPS) is a major trigger of ALI in the progression through macrophage differentiation and the accelerated release of pro-inflammatory cytokines. The present study aimed to investigate the protective effects of human milk oligosaccharides, specifically 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), on LPS-induced ALI and elucidate their underlying signaling pathways. The inhibitory effect...
Source: Archives of Pharmacal Research - November 8, 2023 Category: Drugs & Pharmacology Authors: Yujin Jin Hyesu Jeon Thuy Le Lam Nguyen Lila Kim Kyung-Sun Heo Source Type: research
Death-associated protein kinase 1 phosphorylates MDM2 and inhibits its protein stability and function
Arch Pharm Res. 2023 Oct 7. doi: 10.1007/s12272-023-01469-8. Online ahead of print.ABSTRACTBreast cancer is one of the major malignancies in women, and most related deaths are due to recurrence, drug resistance, and metastasis. The expression of the mouse double minute 2 (MDM2) oncogene is upregulated in breast cancer; however, its regulatory mechanism has yet to be fully elucidated. Herein, we identified the tumor suppressor death-associated protein kinase 1 (DAPK1) as a novel MDM2 regulator by unbiased peptide library screening. DAPK1 is directly bound to MDM2 and phosphorylates it at Thr419. DAPK1-mediated MDM2 phosphor...
Source: Archives of Pharmacal Research - October 7, 2023 Category: Drugs & Pharmacology Authors: Mi Zhang Xindong Shui Xiaoqing Zheng Jong Eun Lee Yingxue Mei Ruomeng Li Yuan Tian Xiuzhi Zheng Quling Wang Long Wang Dongmei Chen Tao Zhang Byeong Mo Kim Jungho Kim Tae Ho Lee Source Type: research
